16 / 18
Page 70
conferenceseries
.com
Volume 2, Issue 4 (Suppl)
Breast Can Curr Res, an open access journal
Breast Pathology 2017
August 23-24, 2017
August 23-24, 2017 Toronto, Canada
4
th
World Congress on
Breast Pathology and Cancer Diagnosis
Breast Can Curr Res 2017, 2:4 (Suppl)
DOI: 10.4172/2572-4118-C1-009
MiR-10b, miR-133a, miR-155 and miR-639 as non-invasive potential biomarkers in breast cancer
Amal Fawzy
1
, Ossama A Mansour
1
, Ahmed I Abulsoud
1
, Mohamed Badr
1
, Reham A A Elshimy
1
, Ahmed Ismail
1
, Hesham A M El-Mahdy
1
and
Amr M
Ali
2
1
Cairo University, Egypt
2
BeniSwif University, Egypt
Background:
Among women, the second leading cause of death worldwide is the breast cancer (BC). MicroRNAs (miRNAs)
expression participates in breast cancer.
Objectives:
The purpose of this study is to investigate the expression of miRNA-10b, miR-133a, miR-155 and miR-639 in breast
cancer and study their correlation with clinicopathological features and tumor suppressor protein (p53) concentration.
Material & Methods:
The four miRNAs levels were measured in serum using quantitative real-time PCR (QRT-PCR) and
(p53) concentration by enzyme-linked immunosorbent assays (ELISA) in women with breast cancer (n=60) and healthy
controls (n=80).
Results:
In this study miRNA-10b, miRNA-155, and miRNA-639 were overexpressed while miR-133a had down expression
in the serum of breast cancer patients compared to control serum. P53 had no significant correlation with any of the studied
miRNAs. A significant association was observed between miR-10b and human epidermal growth factor-2 (HER-2) (P=0.046),
miR-155 with lymph node involvement (P=0.05), and between miR-133a and tumor grade (P=0.039).
Conclusion:
These miRNAs have a significant signature in the pathogenesis of breast cancer and can be used as non-invasive
molecular biomarkers for breast cancer detection.
rehamelshimy@ymail.com